FDA AI Division Faces Cuts Amidst Trump's Tech Investment Push
2025-02-17
STAT
The FDA's AI and digital health division has been significantly impacted by recent layoffs, sparking concerns about the agency's ability to keep pace with innovation. Despite President Trump's efforts to invest in emerging technologies, the FDA's strained relationship with companies like Neuralink, founded by Elon Musk, may hinder progress in the field of artificial intelligence and digital health. As the industry continues to evolve, the FDA must navigate these challenges to ensure public safety and stay ahead of the curve in areas like machine learning and healthcare technology.
